Indications

Monas is indicated for:  
- Prophylaxis and chronic treatment of asthma 
- Acute prevention of Exercise-Induced Bronchoconstriction (EIB) 
- Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis

রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন

Pharmacology

Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor (CysLT1). The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from vario us cells, including mast cells and eosinophils. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma & allergic rhinitis, including airway edema, smooth muscl e contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.

Dosage & Administration

Adults and adolescents with asthma or seasonal allergic rhinitis: 
- 15 years of age and older: Montelukast 10 mg tablet once daily.

Pediatric patients with asthma or seasonal allergic rhinitis:

• 6 to 14 years of age: Montelukast 5 mg tablet once daily.
• 2 to 5 years of age: Montelukast 4 mg tablet once daily.
• 6 months to 5 years of age: Montelukast 4 mg oral granules once daily. This can be administered either directly in the mouth, or mixed with a spoonful of cold water or soft food at room temperature.

Special Populations:

• Pediatric Use: The safety and efficacy of Montelukast have been established in pediatric patients with asthma 6 months to 14 years of age with profiles similar to adults.
• Hepatic Insufficiency: No dosage adjustment is required in mild-to-moderate hepatic insufficiency.
• Renal Insufficiency: No dosage adjustment is recommended.
• Elderly Use: Pharmacokinetic profiles are similar to younger adults; no dosage adjustment is required.
• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন

Interaction

Monas has been administered with other routine asthma therapies with no apparent increase in adverse reactions. It does not have clinically important effects on the pharmacokinetics of theophylline, prednisone, prednisolone, oral contraceptives, terfenadine, digoxin, and warfarin. Concomitant use with thyroid hormones, sedative hypnotics, NSAIDs, benzodiazepines, and decongestants showed no evidence of adverse interactions.

Phenobarbital decreases the AUC of Monas by approximately 40%. While no dosage adjustment is recommended, appropriate clinical monitoring is advised when potent cytochrome P450 enzyme inducers (such as phenobarbital or rifampin) are co-administered.

Contraindications

Montelukast is contraindicated in patients who are hypersensitive to any component of this product.

Side Effects

Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.
Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritabili ty, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.  
Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomat osis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, m emory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.

Pregnancy & Lactation

Montelukast crosses the placenta in animal studies, but there are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if clearly needed. Caution should be exercised when administered to a nursing mother.

Precautions & Warnings

Monas is not indicated for the reversal of bronchospasm in acute asthma attacks (including status asthmaticus); patients should have appropriate rescue medication available. Monas should not be abruptly substituted for inhaled or oral corticosteroids, nor should it be used as monotherapy for exercise-induced bronchospasm. Patients with known aspirin sensitivity should continue avoiding aspirin and NSAIDs.

Overdose Effects

The most frequent adverse experiences in overdose include abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Standard supportive measures should be employed in the event of an overdose.

Therapeutic Class

Leukotriene receptor antagonists

Storage Conditions

Store in a cool and dry place below 30°C. Protect from light and moisture. Keep out of reach of children.

Chemical Structure

Molecular Formula: C35H36ClNO3S

Common Questions about Monas 10 mg Tablet

• What is Monas 10 mg Tablet? It is a selective and orally active leukotriene receptor antagonist.
• What is Monas 10 mg Tablet used for? It is commonly used to treat asthma or allergic rhinitis by blocking leukotrienes to keep airways open.
• How soon can the effect be observed? Within 1 to 3 hours. It is not a fast-acting rescue medicine and must be taken daily.
• How long does the effect last? An average duration of 24 hours.
• Should I take it on an empty stomach? It may be taken with or without food.
• What if I miss a dose? Take it as soon as possible, or skip it if it is almost time for your next dose. Do not double up on doses.
• Are there pregnancy warnings? Avoid use unless clearly needed under doctor supervision.

General Instructions

• Take Monas 10 mg Tablet exactly as prescribed.
• Do not change doses or stop asthma medication without consulting your doctor.
• Seek immediate medical attention if breathing problems worsen quickly.
• Avoid situations or activities that trigger asthma attacks.
• Consult your doctor if you are pregnant or breastfeeding.
• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন